Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.

Abstract: The present disclosure generally relates to plant-based air purification systems and more particularly to wall mounted systems for removing impurities from indoor air using plants.

Abstract: A method to divide liposuction fat into aliquots for use and cryopreservation purposes, the method comprising: providing a taking container that contains adipose material removed by liposuction, the adipose material including fat and aqueous fluid; providing a plurality of cryopreservation containers; taking a quantity of the adipose material from the taking container, keeping the quantity of the adipose material isolated from an external environment; separating by gravity the fat from the aqueous fluid in the adipose material of the taken quantity; and transferring the separated fat into one or more cryopreservation containers, to define isolated aliquots of fat.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.

Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

Abstract: Disclosed herein is a recombinant antibody against the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A kit containing the recombinant antibody for use in coronavirus detection is encompassed in the present disclosure. Also disclosed herein are in vitro methods of detecting coronavirus infection in a subject with the aid of the recombinant antibody.

Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.

Abstract: Disclosed are methods for lysis of cells that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allow for simplified removal of detergent after lysis, and importantly, limits damage to DNA, such as shearing, that typically results from separate application of conventional lysis methods, yielding improved quality and quantities of genomic DNA (gDNA).

Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Abstract: A system comprising a remotely programmable micromonitor with a wireless sensing system-on-module (SOM), one or more sensors to detect one or more conditions in a subject by monitoring one or more parameters associated with the conditions by comparing any monitored parameter to a baseline measurement of the monitored parameter from the subject, a plurality of sensors corresponding to a monitored parameter and connected to the micromonitor to convey measurements of all monitored parameters, the sensors including at least one of a non-optical pulse wave sensor or an electrocardiogram (ECG) sensor, a communications module capable of communicating with a wireless technology, wherein the module can send an alert signal to the subject or an attending physician or a remote service center or any other subject, and one or more algorithms for monitoring conditions and/or for predicting conditions, including at least one of a fall detection or fall prediction algorithm.

Abstract: A dental implant for insertion into bone within a patient's mouth comprises a body and a scannable code. The body includes a bone-engaging exterior surface, an anti-rotational feature for non-rotationally mating with an abutment, and an upper region. The upper region includes an upper surface for engaging the abutment. The scannable code on the upper surface provides information concerning the dental implant. The information includes at least two features of the dental implant.

Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.

Abstract: The present invention is directed to SH3 domain derivatives having a specific binding affinity to a target molecule. In this respect, the invention provides SH3 domain derivatives of nephrocystin (NPHP1) and the Tec kinase. The invention also provides a method for the production of a library comprising recombinant derivatives of NPHP1 or the Tec kinase SH3 domains and a method for selecting from the library one or more derivatives of the SH3 domain of nephrocystin (NPHP1) or the Tec kinase having a specific binding affinity to a target molecule.

Abstract: The invention relates to a kit to prepare an hemostatic flowable comprising: —A hemostatic powder having a composition comprising: ?non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; ?at least one monosaccharide; and ?at least one glycosaminoglycan; —A saline solution to be mixed with the hemostatic powder in order to form the hemostatic flowable. The invention also relates to a method for preparing an hemostatic flowable with such a kit, comprising the steps of: a. Providing the hemostatic powder in a container; b. Adding a quantity of the saline solution in the container enclosing the hemostatic powder, closing and shaking said container in order to promote hydration of the hemostatic powder to form the hemostatic flowable.

Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Abstract: The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.

Abstract: We have created a novel formulation to serve as a sanitizing, disinfectant or cleanser, excluding traditional synthetic chemicals historically addressing this role. The product is all-natural, GRAS certified ingredients that is safe, non-toxic and can be inhaled, ingested, applied topically to the animal body and of course, to all other surfaces we have defined herein. Thereby safe for water bowls, water and feed troughs, and water line flushing and disinfecting/sanitizing or cleaning.

Abstract: The invention relates to a printed hemostatic product having at least three-dimensions and being made of a stack of layers deposited on one another from a first external layer up to a second external layer, wherein adjacent layers of the stack of layers are joined together, and wherein at least one layer of the stack of layers has at least one portion made from an hemostatic flowable with a composition comprising: non-cross-linked collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen; and—at least one monosaccharide. The invention also relates to a method for forming such an hemostatic product with a three-dimensional additive printer, and the use of an hemostatic flowable as a printing ink in such a three-dimensional additive printer.